Latest Ratios: P/E Ratio 37.4x · EV/EBITDA 17.4x · ROE 8.8%. (2013–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $691M | $676M | $413M | $331M | $230M | $375M | $869M | $1.3B | $881M | $547M | $277M |
| Enterprise Value | $624M | $608M | $364M | $321M | $281M | $428M | $843M | $1.3B | $861M | $523M | $246M |
| P/E Ratio → | 37.38 | 35.37 | 24.47 | 11.63 | — | — | — | 120.55 | 133.97 | 93.48 | 96.53 |
| P/S Ratio | 2.10 | 2.05 | 1.41 | 1.21 | 0.93 | 1.80 | 4.65 | 7.00 | 6.13 | 5.01 | 3.27 |
| P/B Ratio | 3.26 | 3.09 | 1.91 | 1.71 | 1.90 | 2.93 | 6.97 | 11.78 | 9.87 | 7.52 | 4.64 |
| P/FCF | 17.10 | 16.71 | 10.84 | 9.93 | 70.05 | 1359.64 | 1728.53 | — | — | 1470.65 | 44.61 |
| P/OCF | 16.15 | 15.78 | 10.17 | 9.24 | 44.23 | 142.63 | 311.19 | 528.28 | 97.84 | 130.51 | 39.33 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.85 | 1.24 | 1.17 | 1.14 | 2.06 | 4.50 | 6.96 | 5.99 | 4.79 | 2.91 |
| EV / EBITDA | 17.37 | 16.93 | 12.57 | 13.07 | 167.67 | 222.85 | — | 94.03 | 129.99 | 91.03 | 48.51 |
| EV / EBIT | 21.31 | 20.77 | 14.24 | 16.10 | — | — | — | 125.72 | 247.75 | 124.85 | 57.07 |
| EV / FCF | — | 15.04 | 9.55 | 9.61 | 85.34 | 1549.43 | 1675.92 | — | — | 1406.26 | 39.67 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 75.2% | 75.2% | 74.0% | 71.1% | 71.3% | 71.2% | 71.0% | 70.8% | 71.1% | 73.4% | 72.9% |
| Operating Margin | 8.9% | 8.9% | 7.6% | 6.6% | -5.2% | -0.8% | -1.9% | 5.5% | 2.1% | 3.6% | 5.1% |
| Net Profit Margin | 5.8% | 5.8% | 5.8% | 10.4% | -7.2% | -5.7% | -0.3% | 5.8% | 4.6% | 5.4% | 3.4% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 8.8% | 8.8% | 8.3% | 18.1% | -14.3% | -9.3% | -0.5% | 10.9% | 8.2% | 8.8% | 6.6% |
| ROA | 6.7% | 6.7% | 5.9% | 10.6% | -7.2% | -5.6% | -0.4% | 8.5% | 6.8% | 7.2% | 5.2% |
| ROIC | 13.8% | 13.8% | 9.5% | 7.6% | -5.4% | -0.9% | -2.7% | 9.0% | 3.8% | 7.5% | 12.8% |
| ROCE | 11.9% | 11.9% | 8.9% | 8.4% | -6.4% | -1.0% | -2.6% | 9.5% | 3.6% | 5.8% | 9.8% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.07 | 0.07 | 0.21 | 0.26 | 0.59 | 0.63 | 0.17 | 0.15 | 0.00 | 0.00 | 0.00 |
| Debt / EBITDA | 0.44 | 0.44 | 1.56 | 2.05 | 43.15 | 42.01 | — | 1.18 | 0.00 | 0.00 | 0.01 |
| Net Debt / Equity | — | -0.31 | -0.23 | -0.06 | 0.41 | 0.41 | -0.21 | -0.05 | -0.23 | -0.33 | -0.51 |
| Net Debt / EBITDA | -1.88 | -1.88 | -1.70 | -0.43 | 30.05 | 27.30 | — | -0.44 | -3.03 | -4.17 | -6.04 |
| Debt / FCF | — | -1.67 | -1.29 | -0.32 | 15.29 | 189.79 | -52.61 | — | — | -64.38 | -4.94 |
| Interest Coverage | 28.21 | 28.21 | 12.27 | 4.80 | -4.55 | — | — | — | — | — | — |
Net cash position: cash ($83M) exceeds total debt ($16M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.03 | 4.03 | 4.36 | 3.54 | 1.86 | 3.29 | 4.63 | 5.06 | 5.28 | 5.29 | 4.66 |
| Quick Ratio | 3.69 | 3.69 | 3.90 | 2.99 | 1.50 | 2.74 | 3.93 | 4.17 | 4.59 | 4.53 | 4.18 |
| Cash Ratio | 2.04 | 2.04 | 2.68 | 1.83 | 0.59 | 1.18 | 2.19 | 2.49 | 2.85 | 3.02 | 3.02 |
| Asset Turnover | — | 1.20 | 0.98 | 0.98 | 0.97 | 0.85 | 1.07 | 1.25 | 1.34 | 1.24 | 1.14 |
| Inventory Turnover | 5.83 | 5.83 | 4.09 | 3.52 | 3.06 | 3.11 | 2.93 | 2.90 | 3.71 | 2.63 | 3.50 |
| Days Sales Outstanding | — | 48.60 | 55.98 | 57.42 | 81.09 | 86.80 | 85.53 | 64.42 | 66.33 | 65.94 | 64.77 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | 3.0% |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 2.7% | 2.8% | 4.1% | 8.6% | — | — | — | 0.8% | 0.7% | 1.1% | 1.0% |
| FCF Yield | 5.8% | 6.0% | 9.2% | 10.1% | 1.4% | 0.1% | 0.1% | — | — | 0.1% | 2.2% |
| Buyback Yield | 3.8% | 3.9% | 0.8% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.3% | 0.1% | 0.0% |
| Total Shareholder Yield | 3.8% | 3.9% | 0.8% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.3% | 0.1% | 3.0% |
| Shares Outstanding | — | $23M | $24M | $23M | $20M | $20M | $19M | $20M | $19M | $19M | $17M |
CMS reimbursement policy volatility
Based on current market data, TCMD trades at a forward P/E of 26.68, which appears to discount the company's high-touch service model relative to broader med-tech peers, suggesting that investors remain cautious about the sustainability of its recent revenue acceleration in the face of potential reimbursement headwinds.
The divergence between TCMD's P/S ratio of 2.07 and its higher P/E multiple suggests that the market is struggling to reconcile the company's robust gross margins with its inconsistent bottom-line profitability. This valuation profile implies that investors are pricing the stock as a specialized service provider rather than a high-growth hardware manufacturer, warranting further investigation into whether the current multiple adequately captures the long-term value of its clinical support infrastructure.
According to recent financial statements, TCMD's ROIC has fluctuated significantly, dropping to -0.7% in 2026Q1 from a peak of 9.2% in 2025Q4, which highlights the difficulty of compounding returns when high operating expenses consistently offset the company's strong gross margin profile in the home-care market.
The volatility in ROIC suggests that the company's capital allocation is highly sensitive to the timing of device placements and the associated sales force costs. Investors should monitor whether the recent expansion into respiratory health can generate sufficient incremental returns to stabilize these metrics, as current trends indicate that the company is struggling to maintain consistent capital efficiency.
As reported in quarterly filings, TCMD's cash conversion cycle reached 96 days in 2026Q1, reflecting the inherent friction in the reimbursement process where the time between device delivery and final insurance collection remains a significant drag on the company's overall operational efficiency and liquidity management.
The elevated DSO and DIO figures suggest that the company's high-touch model, while effective for securing physician referrals, creates a structural delay in cash realization. This inefficiency warrants further investigation, as any tightening of payer authorization policies could further extend the cash conversion cycle and pressure the company's working capital position.
Based on the most recent balance sheet data, TCMD maintains a current ratio of 4.24, providing a substantial liquidity cushion that appears designed to absorb the seasonal volatility and payment delays typical of the durable medical equipment industry's complex insurance authorization and collection cycles.
This strong liquidity position is a critical defensive feature, allowing the company to navigate periods of regulatory scrutiny or shifts in payer mix without the need for external financing. While this conservative approach supports operational stability, it also raises questions about whether the company is effectively deploying its excess cash to drive long-term shareholder value.
The most commonly misapplied metric for TCMD is the standard EV/EBITDA multiple, which obscures the company's true value as a specialized reimbursement platform by treating its high-touch clinical support costs as mere operating overhead rather than as a core investment in its competitive moat.
Using traditional hardware valuation multiples fails to account for the significant administrative and clinical infrastructure that TCMD has built to navigate the 'last mile' of home-based therapy. Analysts should instead focus on metrics that capture the value of the company's payer relationships and clinical data, as these are the primary drivers of its long-term market share durability.
Includes 30+ ratios · 13 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying TCMD stock.
Tactile Systems Technology, Inc.'s current P/E ratio is 37.4x. The historical average is 73.7x. This places it at the 43th percentile of its historical range.
Tactile Systems Technology, Inc.'s current EV/EBITDA is 17.4x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 46.0x.
Tactile Systems Technology, Inc.'s return on equity (ROE) is 8.8%. The historical average is 5.7%.
Based on historical data, Tactile Systems Technology, Inc. is trading at a P/E of 37.4x. This is at the 43th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Tactile Systems Technology, Inc. has 75.2% gross margin and 8.9% operating margin.
Tactile Systems Technology, Inc.'s Debt/EBITDA ratio is 0.4x, indicating low leverage. A ratio below 2x is generally considered financially healthy.